Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM, revenues increased 14%Full year 2023 revenues increased 8% to $13.12 billion versus full...

Related Keywords

Rensselaer , New York , United States , West Virginia , Massachusetts , Tarrytown , Japan , America , American , Christina Chan , Novarti Ilaris , Bryan Crowe , Sanofi Immuno , States Sanofi , Leonards Schleifer , Bob Landry , Roberte Landry , Company Rensselaer , Regeneron Pharmaceuticals Inc , Business Development Updates , European Society For Medical Oncology Immuno , Biocon , Nasdaq , European Union , Regeneron Genetics Center , United States Centers For Medicare Medicaid Services , Checkmate Pharmaceuticals Inc , Corporate Affairs , United States District Court , Linkedin , Biocon Biologics Inc , American Society Of Hematology , Japan Ministry Of Health , Viatris Inc , Board Co , European Commission , Oncology Esmo Io Congress , Alnylam Pharmaceuticals Inc , Mitsubishi Tanabe Pharma Corporation , Mylan Pharmaceuticals Inc , Exchange Commission , Drug Administration , Regeneron Pharmaceuticals , Board Co Chair , Chief Executive Officer , Chief Financial Officer , Executive Vice President , United States Centers , Medicaid Services , Healthcare Common Procedure Coding System , Biologics License Application , American Society , Annual Meeting , European Society , Medical Oncology Immuno , Breakthrough Therapy , Business Development , Biocon Biologics , Northern District , Dow Jones Sustainability World Index , Dow Jones Sustainability North America Index , Effective July , Alnylam Pharmaceuticals , Checkmate Pharmaceuticals , Sanofi Immuno Oncology , Accepted Accounting Principles , Regeneron Genetics , Looking Statements , Product Candidates , Total Sales , Markets ,